871108-05-3

Basic information

• Product Name: trabodenoson
• Synonyms: trabodenoson;((2R,3S,4R,5R)-5-(6-(CYCLOPENTYLAMINO)-9H-PURIN-9-YL)-3,4-DIHYDROXYTETRAHYDROFURAN-2-YL)METHYL NITRATE
• CAS NO: 871108-05-3
• Molecular Formula: C15H20N6O6
• Molecular Weight: 380.3559
• Mol File: 871108-05-3.mol

Chemical Properties

• Boiling Point: 691.2±65.0 °C(Predicted)
• Appearance: /
• Density: 1.87±0.1 g/cm3(Predicted)
• PKA: 12.99±0.70(Predicted)
• CAS DataBase Reference: trabodenoson(CAS DataBase Reference)
• NIST Chemistry Reference: trabodenoson(871108-05-3)
• EPA Substance Registry System: trabodenoson(871108-05-3)

Safety Data

• Hazardous Substances Data: 871108-05-3(Hazardous Substances Data)

Usage

Uses

Used in Ophthalmology:
Trabodenoson is used as a therapeutic agent for the treatment of glaucoma and ocular hypertension. Its ability to alter ECM turnover by TM cells and increase conventional outflow facility contributes to its efficacy in lowering IOP, providing a potential alternative or complementary treatment option for patients with these conditions.

Upstream product

• 2004-06-0 6-Chloropurine riboside 
• 1003-03-8 Cyclopentamine 
• 41552-82-3 N-cyclopentyladenosine 
• 103626-58-0 {(1R,2R,4R,5R)-4-[6-(cyclopentylamino)purin-9-yl]-7,7-dimethyl-3,6,8-trioxabicyclo[3.3.0]oct-2-yl}methan-1-ol 
• 871108-04-2 2′,3′-O-isopropylidene-N⁶-cyclopentyladenosine-5′-nitrate 

Relevant articles and documents

METHODS OF PREVENTING, REDUCING OR TREATING MACULAR DEGENERATION

The present invention is directed to selective adenosine A1 agonist compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat, reduce or prevent age-related macular degeneration.

METHOD OF PROVIDING OCULAR NEUROPROTECTION

Provided herein are compounds of Formula I, compositions comprising an effective amount of a compound of Formula I, and methods for preventing, reducing or treating retinal ganglion cell damage comprising administering an effective amount of a purine deri

OPHTHALMIC FORMULATIONS

The present invention relates to an ophthalmic formulation which comprises a fine particle of Compound A in an aqueous suspension and a manufacturing process thereof. More specifically, the present invention relates to a topically applied ophthalmic aqueous suspension which is obtainable by suspending fine particles of Compound A in an aqueous vehicle containing a surfactant and boric acid. The invention also provides processes for making the ophthalmic formulations and to methods of use thereof.

ANHYDROUS POLYMORPHS OF [(2R,3S,4R,5R)-5-(6-(CYCLOPENTYLAMINO)-9H-PURIN-9-YL)-3,4-DIHYDROXYTETRAHYDROFURAN-2-YL)} METHYL NITRATE AND PROCESSES OF PREPARATION THEREOF

The present invention provides novel anhydrous polymorph forms of 2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl nitrate (Compound A). The present invention also provides processes for preparation of the anhydrous polymorphic forms of compound A.

COMBINATION, KIT AND METHOD OF REDUCING INTRAOCULAR PRESSURE

The present invention is directed to a combination or a kit comprising a prostaglandin analog and an adenosine receptor A1 agonist and to a method of reducing intraocular pressure (IOP) in a subject using such combination or kit. The invention is particularly directed to a combination of latanoprost marketed under the brand Xalatan? and Compound A.

METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS

Provided herein are compounds of Formula I, compositions comprising an effective amount of a compound of Formula I, and methods for reducing intraocular pressure comprising administering an effective amount of compounds of Formula I to a subject in need t

Purine compounds and methods of use thereof

The invention relates to Purine Compounds; compositions comprising an effective amount of a Purine Compound; and methods for reducing a subject's rate of metabolism or protecting a subject's heart against myocardial damage during cardioplegia; or for treating or preventing a cardiovascular disease, a neurological disorder, an ischemic condition, a reperfusion injury, obesity, a wasting disease, diabetes, a cellular proliferative disorder, a skin disorder, a radiation-induced injury, a wound or an inflammatory disease comprising administering an effective amount of a Purine Compound to a subject in need thereof.

PURINE DERIVATIVES AS ADENOSINE A1 RECEPTOR AGONISTS AND METHODS OF USE THEREOF

The invention relates to Purine Derivatives, compositions comprising an effective amount of a Purine Derivative; and methods for reducing an animal’s rate of metabolism, protecting an animal’s heart against myocardial damage during cardioplegia; or for treating or preventing a cardiovascular disease, a neurological disorder, an ischemic condition, a reperfusion injury, obesity, or wasting disease, or diabetes, comprising administering an effective amount of a Purine Derivative to an animal in need thereof.